Drug intelligence / Profile preview

Endogard

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

Endogard is a brand name for a veterinary anthelmintic drug primarily used for the treatment and control of various intestinal worms in dogs and cats. One common formulation combines the active ingredients praziquantel and oxibendazole. Praziquantel works by inducing contractions and paralysis in tapeworms and flukes, leading to their dislodgement and destruction. Oxibendazole, a benzimidazole, is effective against roundworms, strongyles, threadworms, pinworms, and lungworms by interfering with their energy metabolism. This combination provides broad-spectrum protection against common parasites like roundworms, hookworms, whipworms, and tapeworms, including hydatids. Other formulations of Endogard may include additional active ingredients such as febantel, pyrantel, and ivermectin, offering broader coverage against different types of parasites and even heartworm prevention. The drug is typically administered orally as a palatable tablet.

Brand names
Endogard
Other names
Endoguard
02

Targets

TUBB1 (β-tubulin 1)

Beyond the preview

Go deeper on Endogard.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endogard.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call